Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Chalazion × Sevoflurane × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 11 Breast Neoplasms 8 Colonic Neoplasms 7 Lung Neoplasms 6 Brain Neoplasms 4 Urinary Bladder Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Hepatocellular 3 Respiratory Aspiration 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Postoperative Complications 2 Pituitary Neoplasms 2 Ovarian Neoplasms 2 Neoplastic Cells, Circulating 2 Neoplasm Metastasis 2 Melanoma 2 Uterine Neoplasms 1 Thyroid Nodule 1 Thyroid Neoplasms 1 Recurrence 1 Quality of Recovery 1 Postoperative Cognitive Complications 1 Pain, Postoperative 1 Neurofibromatoses 1 Myofibroma 1 Lymphoma, Follicular 1 Liver Neoplasms 1 Liver Functions Tests 1 Kidney Neoplasms 1

Interventions

Conservative Treatment 3 tyramine-deoxysorbitol 2 Probiotics 2 Curettage 2 Triamcinolone Acetonide 1 Triamcinolone 1 Tetracycline 1 Sevoflurane 1 Loteprednol Etabonate 1 Fluorouracil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07450495 2026-03-04

SEVO-PED

Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong

Phase NA Recruiting

Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡